[2026 update] US compounding rules and how they changed

Cost comparisons should state whether they include the device and the dispensing fee, because those differ between routes and between states.

Post #12 put the caveat in the right place and I want to underline it.

Appeals succeed more often than people expect when they answer the stated criterion point by point and include nothing else.

I would treat that as a working assumption and revisit it.

Say which country and which state or province. Regulatory position, availability and practical route can all differ within the same continent and frequently do.

Where a compounding pathway existed and closed, posts describing it stay in the archive and should be read with their date attached.

Picking up post #18: that is the part I would want checked first.

Emotional language in an appeal does not help, however justified it is. The reviewer is checking criteria and the job is to make them checkable.

I would rather post the uncertainty than round it away.

On post #16 — agreed on the reasoning, with one qualification.

Compounded preparations and authorised products are different regulatory categories with different oversight, and conflating them produces most of the confusion here.

If anyone can point at the primary source I would be grateful.

Compounding pharmacies: pharmaceutical compounding of a drug not on the FDA shortage list is substantially constrained. The landscape changed when supply normalised. Current compounding availability is limited.

That is the version I would defend. It is not the version I started with.

Date every claim in this subcategory. Positions here have moved repeatedly and old posts are read as current.

I have deliberately not rounded that, because the rounding is where the argument starts.

I came in to disagree and I am leaving without a disagreement.

Adding the measurement that post #21 says would settle it.

Cross-border purchasing raises both a legal question and a practical one, and the legal one is yours to establish for your own jurisdiction.

Pharmacy practice varies between pharmacies within the same city, so two honest accounts can be entirely different.

Where a manufacturer runs a direct supply route, that is a commercial arrangement rather than a regulatory change, and it can end.

I would put this at better than even and not much better.

The denial letter is the specification for the appeal. It states a criterion and the job is to demonstrate that criterion in the letter's own language.

Old habit: I write down the expected answer before I calculate it.

The arithmetic in post #25 is right; the assumption feeding it is the part to check.

Compounding pharmacies: pharmaceutical compounding of a drug not on the FDA shortage list is substantially constrained. The landscape changed when supply normalised. Current compounding availability is limited.

I have said this before in a thread nobody could find, so it is worth repeating.

I read post #25 twice before replying, because I had assumed the opposite.

Emotional language in an appeal does not help, however justified it is. The reviewer is checking criteria and the job is to make them checkable.

Post #29 answers the question as asked. The question underneath it is different.

Cost comparisons should state whether they include the device and the dispensing fee, because those differ between routes and between states.